Literature DB >> 2327773

Efficacy of ofloxacin in experimental Staphylococcus aureus endocarditis.

G W Kaatz1, S M Seo, S L Barriere, L M Albrecht, M J Rybak.   

Abstract

The efficacy of ofloxacin was compared with that of vancomycin in the therapy of experimental Staphylococcus aureus endocarditis. Rabbits infected with either a methicillin-susceptible (MSSA-1199) or a methicillin-resistant (MRSA-494) test strain were treated with ofloxacin (20 mg/kg of body weight every 8 h) or vancomycin (17.5 mg/kg of body weight every 6 h) for 4 days. The antimicrobial agents were found to be equally effective in clearing bacteremia and in reducing bacterial counts in vegetations and in renal and splenic tissue of animals infected with either test strain. The drugs were of equal efficacy in curing MRSA-494 endocarditis. No resistance to ofloxacin emerged in either test strain during therapy. We conclude that in this model ofloxacin is as efficacious as vancomycin and that, unlike for other fluoroquinolones we have evaluated, resistance to the drug does not develop during therapy of this serious S. aureus infection.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2327773      PMCID: PMC171568          DOI: 10.1128/AAC.34.2.257

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  11 in total

1.  Comparative antibacterial activity of new quinolone-carboxylic acid derivatives.

Authors:  S Mitsuhashi
Journal:  Rev Infect Dis       Date:  1988 Jan-Feb

2.  Automated fluorescence polarization immunoassay for monitoring vancomycin.

Authors:  K S Schwenzer; C H Wang; J P Anhalt
Journal:  Ther Drug Monit       Date:  1983       Impact factor: 3.681

3.  Serum dilution test for bactericidal activity. I. Selection of a physiologic diluent.

Authors:  C W Stratton; L B Reller
Journal:  J Infect Dis       Date:  1977-08       Impact factor: 5.226

4.  Ciprofloxacin and rifampin, alone and in combination, for therapy of experimental Staphylococcus aureus endocarditis.

Authors:  G W Kaatz; S M Seo; S L Barriere; L M Albrecht; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

5.  Resistance studies with ofloxacin.

Authors:  D Felmingham; P Foxall; M D O'Hare; G Webb; G Ghosh; R N Grüneberg
Journal:  J Antimicrob Chemother       Date:  1988-09       Impact factor: 5.790

6.  Pefloxacin therapy for experimental endocarditis caused by methicillin-susceptible or methicillin-resistant strains of Staphylococcus aureus.

Authors:  P M Sullam; M G Täuber; C J Hackbarth; H F Chambers; K G Scott; M A Sande
Journal:  Antimicrob Agents Chemother       Date:  1985-05       Impact factor: 5.191

7.  The emergence of resistance to ciprofloxacin during treatment of experimental Staphylococcus aureus endocarditis.

Authors:  G W Kaatz; S L Barriere; D R Schaberg; R Fekety
Journal:  J Antimicrob Chemother       Date:  1987-11       Impact factor: 5.790

8.  Comparative evaluation of recently developed quinolone compounds--with a note on the frequency of resistant mutants.

Authors:  W Cullmann; M Stieglitz; B Baars; W Opferkuch
Journal:  Chemotherapy       Date:  1985       Impact factor: 2.544

9.  Efficacy of fleroxacin in experimental methicillin-resistant Staphylococcus aureus endocarditis.

Authors:  G W Kaatz; S M Seo; S L Barriere; L M Albrecht; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  1989-04       Impact factor: 5.191

10.  Enoxacin compared with vancomycin for the treatment of experimental methicillin-resistant Staphylococcus aureus endocarditis.

Authors:  M Gilbert; J A Boscia; W D Kobasa; D Kaye
Journal:  Antimicrob Agents Chemother       Date:  1986-03       Impact factor: 5.191

View more
  14 in total

Review 1.  Pharmacokinetic and pharmacodynamic requirements for antibiotic therapy of experimental endocarditis.

Authors:  A C Cremieux; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1992-10       Impact factor: 5.191

Review 2.  Current perspectives on glycopeptide resistance.

Authors:  N Woodford; A P Johnson; D Morrison; D C Speller
Journal:  Clin Microbiol Rev       Date:  1995-10       Impact factor: 26.132

3.  Efficacy of LY333328 against experimental methicillin-resistant Staphylococcus aureus endocarditis.

Authors:  G W Kaatz; S M Seo; J R Aeschlimann; H H Houlihan; R C Mercier; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

Review 4.  Ofloxacin clinical pharmacokinetics.

Authors:  K C Lamp; E M Bailey; M J Rybak
Journal:  Clin Pharmacokinet       Date:  1992-01       Impact factor: 6.447

5.  Development of resistance to fleroxacin during therapy of experimental methicillin-susceptible Staphylococcus aureus endocarditis.

Authors:  G W Kaatz; S M Seo; S L Barriere; L M Albrecht; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  1991-08       Impact factor: 5.191

6.  Pharmacodynamics of once- or twice-daily levofloxacin versus vancomycin, with or without rifampin, against Staphylococcus aureus in an in vitro model with infected platelet-fibrin clots.

Authors:  S M Palmer; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

7.  Pharmacodynamics of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with rifampin, against methicillin-susceptible and -resistant Staphylococcus aureus in an in vitro infection model.

Authors:  S L Kang; M J Rybak; B J McGrath; G W Kaatz; S M Seo
Journal:  Antimicrob Agents Chemother       Date:  1994-12       Impact factor: 5.191

8.  Comparative prophylactic efficacies of ciprofloxacin, ofloxacin, cefazolin, and vancomycin in experimental model of staphylococcal wound infection.

Authors:  D S Kernodle; A B Kaiser
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191

9.  CI-960, a new fluoroquinolone, for therapy of experimental ciprofloxacin-susceptible and -resistant Staphylococcus aureus endocarditis.

Authors:  G W Kaatz; S M Seo; K C Lamp; E M Bailey; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  1992-06       Impact factor: 5.191

Review 10.  Evaluation of quinolones in experimental animal models of infections.

Authors:  W M Scheld
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-04       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.